Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA

(marketscreener.com) - Upstaza™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency -- MHRA authorization follows recent European Union authorization -- AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD, N.J., Nov. 17, 2022 /PRNewswire/...https://www.marketscreener.com/quote/stock/PTC-THERAPEUTICS-INC-13450034/news/Upstaza-trade-Gene-Therapy-Granted-Marketing-Authorization-for-AADC-deficiency-by-UK-s-MHRA-42344585/?utm_medium=RSS&utm_content=20221117